Krystal Biotech, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Pittsburgh PA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03536143
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Associate Director, Clinical Operations, Krystal Biotech | Krystal Biotech, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

beremagene geperpavec (2 trials)

Drugs in Phase 2 Trials (2)

hsv1-col7 (1 trial)

kb105 (1 trial)

Drugs in Phase 1 Trials (2)

kb301 (1 trial)

kb407 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 1)

Atrophy (Phase 1)

Cicatrix, Hypertrophic (Phase 1)

Epidermolysis Bullosa (Phase 3)

Epidermolysis Bullosa Dystrophica (Phase 3)

Ichthyosiform Erythroderma, Congenital (Phase 2)

Ichthyosis (Phase 2)

Ichthyosis, Lamellar (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5